Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma
暂无分享,去创建一个
M. Dimopoulos | A. Belch | J. S. San Miguel | J. Zeldis | T. Facon | D. Weber | E. Stadtmauer | R. Knight | Zhinuan Yu | R. Niesvizky | M. Olesnyckyj | M. Prince | Marta Olesnyckyj
[1] Michael L. Wang,et al. Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure. , 2008, Blood.
[2] Bin Jiang,et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. , 2008, The New England journal of medicine.
[3] M. Boccadoro,et al. Thalidomide for treatment of multiple myeloma: 10 years later. , 2008, Blood.
[4] Alessandro Corso,et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. , 2007, The New England journal of medicine.
[5] Michael Wang,et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. , 2007, The New England journal of medicine.
[6] Anthony Boral,et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. , 2007, Blood.
[7] P. L. Bergsagel,et al. Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma. , 2007, Mayo Clinic proceedings.
[8] B. Barlogie,et al. International uniform response criteria for multiple myeloma , 2006, Leukemia.
[9] Robert A Kyle,et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. , 2005, Blood.
[10] Hartmut Goldschmidt,et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. , 2005, The New England journal of medicine.
[11] M. Dimopoulos,et al. Current treatment options for myeloma , 2005, Expert Opinion on Pharmacotherapy.
[12] B. Barlogie,et al. Antitumor activity of thalidomide in refractory multiple myeloma. , 1999, The New England journal of medicine.
[13] S. Jagannath,et al. CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION , 1998, British journal of haematology.
[14] A. Palumbo,et al. Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma. , 2001, Haematologica.